134 related articles for article (PubMed ID: 25478964)
21. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Bhat UG; Winter MA; Pearce HL; Beck WT
Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894
[TBL] [Abstract][Full Text] [Related]
22. Development, characterization and in vitro evaluation of single or co-loaded imatinib mesylate liposomal formulations.
Pinto AC; Angelo S; Moreira JN; Simões S
J Nanosci Nanotechnol; 2012 Mar; 12(3):2891-900. PubMed ID: 22755139
[TBL] [Abstract][Full Text] [Related]
23. Quality-by-Design-Based Development of n-Propyl-Gallate-Loaded Hyaluronic-Acid-Coated Liposomes for Intranasal Administration.
Sabir F; Katona G; Pallagi E; Dobó DG; Akel H; Berkesi D; Kónya Z; Csóka I
Molecules; 2021 Mar; 26(5):. PubMed ID: 33800788
[TBL] [Abstract][Full Text] [Related]
24. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
25. Hyaluronic Acid Surface Modified Liposomes Prepared via Orthogonal Aminoxy Coupling: Synthesis of Nontoxic Aminoxylipids Based on Symmetrically α-Branched Fatty Acids, Preparation of Liposomes by Microfluidic Mixing, and Targeting to Cancer Cells Expressing CD44.
Bartheldyová E; Effenberg R; Mašek J; Procházka L; Knötigová PT; Kulich P; Hubatka F; Velínská K; Zelníčková J; Zouharová D; Fojtíková M; Hrebík D; Plevka P; Mikulík R; Miller AD; Macaulay S; Zyka D; Drož L; Raška M; Ledvina M; Turánek J
Bioconjug Chem; 2018 Jul; 29(7):2343-2356. PubMed ID: 29898364
[TBL] [Abstract][Full Text] [Related]
26. Liposome composition is important for retention of liposomal rhodamine in P-glycoprotein-overexpressing cancer cells.
Kang DI; Kang HK; Gwak HS; Han HK; Lim SJ
Drug Deliv; 2009 Jul; 16(5):261-7. PubMed ID: 19538007
[TBL] [Abstract][Full Text] [Related]
27. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
Kim KA; Park SJ; Kim C; Park JY
Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
[TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate.
Al-Hadiya BM; Bakheit AH; Abd-Elgalil AA
Profiles Drug Subst Excip Relat Methodol; 2014; 39():265-97. PubMed ID: 24794909
[TBL] [Abstract][Full Text] [Related]
29. Hyaluronic acid tethered pH-responsive alloy-drug nanoconjugates for multimodal therapy of glioblastoma: An intranasal route approach.
Pandey A; Singh K; Patel S; Singh R; Patel K; Sawant K
Mater Sci Eng C Mater Biol Appl; 2019 May; 98():419-436. PubMed ID: 30813043
[TBL] [Abstract][Full Text] [Related]
30. Maximizing the Therapeutic Efficacy of Imatinib Mesylate-Loaded Niosomes on Human Colon Adenocarcinoma Using Box-Behnken Design.
Kassem MA; El-Sawy HS; Abd-Allah FI; Abdelghany TM; El-Say KM
J Pharm Sci; 2017 Jan; 106(1):111-122. PubMed ID: 27544432
[TBL] [Abstract][Full Text] [Related]
31. Polycationic nanodrug covered with hyaluronic acid for treatment of P-glycoprotein overexpressing cancer cells.
Yim H; Na K
Biomacromolecules; 2010 Sep; 11(9):2387-93. PubMed ID: 20687538
[TBL] [Abstract][Full Text] [Related]
32. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
33. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
He M; Zhao Z; Yin L; Tang C; Yin C
Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
[TBL] [Abstract][Full Text] [Related]
34. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
[TBL] [Abstract][Full Text] [Related]
35. Influence of charge on encapsulation and release behavior of small molecules in self-assembled layer-by-layer microcapsules.
Mandapalli PK; Labala S; Vanamala D; Koranglekar MP; Sakimalla LA; Venuganti VV
Drug Deliv; 2014 Dec; 21(8):605-14. PubMed ID: 24328418
[TBL] [Abstract][Full Text] [Related]
36. Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment.
Jose A; Ninave KM; Karnam S; Venuganti VVK
J Liposome Res; 2019 Jun; 29(2):153-162. PubMed ID: 30022700
[TBL] [Abstract][Full Text] [Related]
37. Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug.
Smith KD; Paterson S
Haematologica; 2005 Nov; 90 Suppl():ELT01. PubMed ID: 16266931
[No Abstract] [Full Text] [Related]
38. Hyaluronic acid derivative-coated nanohybrid liposomes for cancer imaging and drug delivery.
Park JH; Cho HJ; Yoon HY; Yoon IS; Ko SH; Shim JS; Cho JH; Park JH; Kim K; Kwon IC; Kim DD
J Control Release; 2014 Jan; 174():98-108. PubMed ID: 24280260
[TBL] [Abstract][Full Text] [Related]
39. Killing colon cancer cells through PCD pathways by a novel hyaluronic acid-modified shell-core nanoparticle loaded with RIP3 in combination with chloroquine.
Hou X; Yang C; Zhang L; Hu T; Sun D; Cao H; Yang F; Guo G; Gong C; Zhang X; Tong A; Li R; Zheng Y
Biomaterials; 2017 Apr; 124():195-210. PubMed ID: 28199887
[TBL] [Abstract][Full Text] [Related]
40. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
